HRA Pharma Launches ellaOne(R) in EuropeSeptember 30th, 2009 PARIS -
- New Generation Emergency Contraception now Commercially Available in France, Germany and the United Kingdom, in Anticipation of Upcoming Launch Throughout European Union
HRA Pharma (www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
Dutch Bring Drinking Water Solutions to RomaniaSeptember 29th, 2009 THE HAGUE, The Netherlands - Fresh water from the tap will soon be available everywhere in Romania. From 6 to 9 October, a team of Dutch water experts will visit four southern Provinces (Giurgu, Calarasi, Buzao, and Ilfov) to demonstrate how even the most remote municipalities can offer their residents clean and fresh drinking water.
Sao Paulo Hosts Second CPhI and P-MEC South America Pharma EventsAugust 5th, 2009 MAARSSEN, Netherlands -
Against the background of continuing strong market growth, Sao Paulo will host the second CPhI South America and P-MEC South America pharma ingredients and production technology events on Wednesday 26 - Friday 28 August. Staged by UBM International Media, the debut events in Rio last August welcomed over 180 exhibitors and nearly 4,500 attendees.
HRA Pharma Granted European Marketing Authorization for ellaOne(R)May 25th, 2009 PARIS - Next Generation Emergency Contraceptive Will First be Launched in UK, Germany and France as Company Expands International Operations
HRA Pharma (www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate), its next generation emergency contraceptive, has been granted marketing authorization by the European Commission. The unanimous decision by all member states enables HRA Pharma to begin marketing ellaOne throughout the European Union, making it the only approved product to have been specifically designed and developed for use as an emergency contraceptive.
Teikoku Pharma USA Acquires Travanti Pharma Inc.May 7th, 2009 SAN JOSE, California - Teikoku Pharma USA Inc., the international specialty pharmaceutical company today announced that it has acquired effective May 8, 2009; Minneapolis area based Travanti Pharma Inc., a privately held corporation that designs, develops and markets innovative drug delivery platforms that improve the safety, compliance, effectiveness and ease of administration of medications delivered to the body. The Company has developed a proprietary Wearable Electronic Disposable Drug delivery technology (WEDD(R)) Platform.
LIGHTFAIR International Celebrates 20 Years of Lighting Innovation, Education, LeadershipApril 22nd, 2009 ATLANTA - This May, the world's largest annual architectural and commercial lighting trade show and conference, LIGHTFAIR(R) International (LFI), celebrates 20 years of lighting innovation as it opens the doors to thousands of lighting industry professionals. On its 20th Anniversary, LFI promises to offer its most comprehensive conference programming and largest trade show floor.
Ballast Nedam: Annual Report 2008 Available on WebsiteApril 7th, 2009 NIEUWEGEIN, The Netherlands - As of today both the Dutch and English versions of the annual report are available for reference on www.ballast-nedam.nl. On the website you will also find the agenda and explanatory notes, together with the other documents for the General Meeting of Shareholders on Wednesday 6 May.
Dutch Consortium Builds Registry Framework for Care of Rare DiseasesApril 5th, 2009 LEIDEN, The Netherlands - The Dutch Orphan Disease Registry Consortium is set up in order to build a disease registry framework to collect information on rare diseases, encourage drug development and optimize patient care. The consortium focuses on inborn errors of metabolism as target group of diseases.
BioCis Pharma Starts Phase IIa Trial in PsoriasisMarch 11th, 2009 TURKU, Finland - BioCis Pharma Ltd., a privately-held drug development company with its
headquarters in Turku, Finland, announced that it has begun a new Phase IIa
clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical
drug for dermatology. The double-blind, vehicle-controlled study is designed
to evaluate the tolerability, pharmacokinetics, and efficacy of the topical
product in a total of 18 subjects with mild to moderate plaque psoriasis.
Further 100 Million Euros Allocated to Netherlands-Based R&D Targeting the Early Diagnosis and Treatment of DiseaseMarch 9th, 2009 EINDHOVEN, The Netherlands - The Center for Translational Molecular Medicine (CTMM) - the Dutch
public-private partnership committed to the research and development of new
techniques for the diagnosis and treatment of major diseases - today
announced that eight new research projects will receive funding from the
CTMM. It means that almost 250 million Euros have now been allocated to
Netherlands-based translational projects that could radically improve patient
outcomes for diseases such as Alzheimer's, rheumatoid arthritis, sepsis,
cardiovascular disorders and the most important forms of cancer.